

May 30, 2024

To,
The Chief General Manager
Listing Operation,
BSE Limited,
20th Floor, P. J. Towers,
Dalal Street,
Mumbai – 400 001.
Scrip Code: 524743

Dear Sir/ Madam,

Sub: Outcome of Board Meeting held on 30th May, 2024

Pursuant to Regulation 30 & 33 read with Para A of Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board of Directors have inter-alia approved and taken on record the following at its meeting held today (30/05/2024):

1. Financial Results

Audited Financial Results (Standalone and Consolidated) for the Quarter and Financial Year ended 31/03/2024, Statement of Assets & Liabilities and Statement of Cash Flow for the year ended on March 31st 2024 along with Auditors Report (Standalone and Consolidated) thereon and Declaration in respect of Audit Report (Standalone and Consolidated) with unmodified opinion under Regulation 33(3)(d) of the Listing Regulations are enclosed herewith as **Annexure-1**.

We hereby confirm and declare that the Statutory Auditors of the Company i.e., M/s. Bilimoria Mehta & Co., Chartered Accountants, Mumbai, have issued their audit report on Standalone and Consolidated Financial Statements of the Company for the year ended 31st March 2024 with an unmodified opinion.

Details of Outstanding Qualified Borrowings and Incremental Qualified Borrowings for the financial year ended 31st March 2024 is enclosed **Annexure- 2**.

2. The Board of Directors on the recommendations of Nomination Remuneration Committee have recommended the appointment of **Dr. Jacob Thomas (DIN: 10639814)** as Non-Executive Independent Director of the Company for a term of Five years for the approval of Shareholders through Postal Ballot Process. Further, details required under Regulation 30 of SEBI Listing Regulations, 2015, are given as **Annexure- 3**.

-
3. The Board of Directors on the recommendations of Nomination Remuneration Committee have recommended the appointment of **Mr. Roberto M Pagdanganan (DIN: 10639820)** as Non-Executive Independent Director of the Company for a term of Five years for the approval of shareholders through Postal Ballot Process. Further, details required under Regulation 30 of SEBI Listing Regulations, 2015, are given as **Annexure- 4**.

The date of the ensuing Annual General Meeting will be intimated to the Stock Exchanges in due course of time.

The Board Meeting commenced at 5.30 PM (IST) and concluded at 8.10 PM (IST)

Please take on record.

Thanking You,
Yours Truly,

For **FISCHER MEDICAL VENTURES LIMITED**

(Formerly known as Fischer Chemic Limited)



RAVINDRAN GOVINDAN
CHAIRMAN & MANAGING DIRECTOR



FISCHER MEDICAL VENTURES LIMITED (formerly known as Fischer Chemic Limited)
CIN: 186910MH1993PLC288371

Regd Off: 104, First Floor Raghuleela Mega Mall Behind Poisar Depot Kandivali West, Mumbai, Maharashtra, India, 400067
Corp off: Level 5, Prestige Palladium Bayan, No. 129-140 Greens Road, Chennai, Tamil Nadu, 600006, India
Email: cs@fischermv.com | fischerchemltd@gmail.com | Website: www.fischerchemic.in

Audited Standalone and Consolidated Financial Results for the Quarter and Year Ended 31.03.2024 pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015.

Rs. In Lakhs

SL NO	PARTICULARS	STANDALONE					CONSOLIDATED				
		Quarter Ended			Year Ended		Quarter Ended			Year Ended	
		31.03.2024	31.12.2023	31.03.2023	31.03.2024	31.03.2023	From 26.01.2024 to 31.03.2024 (See Note -1)	31.12.2023	31.03.2023	31.03.2024	31.03.2023
	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	
I	Revenue From Operations	1,134.02		17.95	1,152.83	17.95	2,079.32	-	-	2,098.13	-
II	Other Income	72.35	1.37	-	75.05	-	46.78	-	-	50.12	-
III	Total Income (I + II)	1,206.36	1.37	17.95	1,227.87	17.95	2,126.10	-	-	2,148.25	-
IV	Expenses										
	Cost Of Materials Consumed	1,072.36	-	-	1,072.36	-	1,573.80	-	-	1,573.80	-
	Purchase of Traded Assets	-	-	-	-	-	7.87	-	-	7.87	-
	Changes in Inventories of finished goods, by-products and work in progress	-	-	-	-	-	63.74	-	-	63.74	-
	Employee Benefits Expense	1.29	2.68	0.74	5.50	4.75	33.86	-	-	38.10	-
	Depreciation and Amortisation Expenses	0.06	0.02	-	0.08	-	18.19	-	-	18.21	-
	Finance Costs	(0.00)	-	0.60	1.58	1.65	5.18	-	-	6.76	-
	Other Expenses	70.01	11.91	3.66	94.49	11.67	148.18	-	-	228.66	-
	Total Expenses	1,143.72	14.61	5.00	1,174.01	18.08	1,850.81	-	-	1,937.13	-
V	Profit / (Loss) Before Exceptional Items & Tax (III - IV)	62.65	(13.25)	12.95	53.87	(0.13)	275.29	-	-	211.12	-
VI	Exceptional Items	-	-	-	-	-	-	-	-	-	-
VII	Profit / (Loss) Before Tax (V - VI)	62.65	(13.25)	12.95	53.87	(0.13)	275.29	-	-	211.12	-
VIII	Tax Expense										
	Current Tax	(3.00)	-	-	(3.00)	-	3.00	-	-	3.00	-
	Deferred Tax (Asset) / Liability	(0.02)	(0.03)	(0.88)	(10.59)	(3.52)	13.76	-	-	24.33	-
IX	Profit / (Loss) For The Period From Continuing Operations (VII - VIII)	59.63	(13.28)	12.08	40.28	(3.65)	258.53	-	-	183.79	-
X	Profit / (Loss) From Discontinued Operations	-	-	-	-	-	-	-	-	-	-
XI	Tax Expense Of Discontinued Operations	-	-	-	-	-	-	-	-	-	-
XII	Profit / (Loss) From Discontinued Operations After Tax (X - XI)	-	-	-	-	-	-	-	-	-	-
XIII	Profit / (Loss) For The Period (IX + XII)	59.63	(13.28)	12.08	40.28	(3.65)	258.53	-	-	183.79	-
XIV	Items That Will Not Be Reclassified To Profit / (Loss)										
	(i) Remeasurement of Defined Benefit Plan - Actuarial Gains / (Losses)	-	-	-	-	-	-	-	-	-	-
	(ii) Income Tax Relating On Above	-	-	-	-	-	-	-	-	-	-
	(iii) Equity Instruments Through Other Comprehensive Income	-	-	-	-	-	-	-	-	-	-
	Other Comprehensive Income - Total	-	-	-	-	-	-	-	-	-	-
XV	Total Comprehensive Income For The Period (Comprising Profit / (Loss) For The Period (After Tax) And Other Comprehensive Income For The Period (After Tax))	59.63	(13.28)	12.08	40.28	(3.65)	258.53	-	-	186.04	-
XVI	Paid Up Equity Share Capital (Face Value Re.1/-)	5,350.00	17.20	17.20	5,350.00	17.20	5,350.00	-	-	5,350.00	-
XVII	Other Equity										
XVIII	Earnings Per Share (EPS) From Continuing Operations & Discontinued Operations (In Rs.)										
	Basic	0.15	(0.76)	7.02	0.36	(2.12)	0.65	-	-	1.65	-
	Diluted	0.15	(0.76)	7.02	0.36	(2.12)	0.64	-	-	1.68	-

Notes:

- The acquisition of 'Time Medical International Ventures India Private Limited' has been done during the quarter four of the current financial year ended 31st March 2024. Since consolidation has been done in the current quarter, no comparatives of previous quarter ended 31st December 2023 and relevant corresponding comparative figures of previous periods i.e., quarter ended 31st March 2023 and year ended 31st March 2023 has not been presented in the financial result.
- Figures for the previous periods have been reclassified, wherever necessary, to conform to the current period's classification.
- The above statement has been prepared to the extent applicable, in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised Accounting Practices and Policies adopted by the Company.
- The figures for the quarter ended 31.03.2024 and 31.03.2023 are balancing figure between Audited Figures in respect of full financial year and the published year-to-date figures upto the third quarter of the relevant financial year.
- The above Audited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at its meeting held on 30th May 2024.
- The Statutory Auditor of the Company audited the above Standalone and Consolidated Financial Results for the Year ended 31.03.2024 and the Audit Report with an unmodified opinion was placed before the Board.

CA - Prakosh Mehta.
M. No - 030382

// BY ORDER OF THE BOARD //



For and on behalf of the Board
Fischer Medical Ventures Limited
(Formerly known as Fischer Chemic Limited)





Chairman & Managing Director
DIN : 03137661



Date: 30.05.2024

UDIN :- 24030382BK FJBT5066.

Amount (In Lakhs)

Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) CIN: L86900MH1993PLC288371 STANDALONE BALANCE SHEET AS AT MARCH 31, 2024		
Particulars	As At 31st March 2024	As At 31st March 2023
Assets		
(1) Non-Current Assets		
Property, Plant & Equipment	0.58	-
Deferred Tax Asset (Net)	-	10.57
Financial Assets		
Investment	4,128.26	-
Total Non-Current Assets	4,128.84	10.57
(2) Current assets		
(a) Financial assets		
(i) Trade receivables	1,270.10	17.06
(ii) Cash and cash equivalents	0.38	3.58
(iii) Other Current Financial Asset		
-Loans	3,777.74	-
-Other Current Financial Asset	0.58	0.50
(b) Other Current Assets	5.51	3.65
Total Current Assets	5,054.31	24.78
Total Assets	9,183.16	35.35
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share Capital	5,350.00	17.20
(b) Other Equity		
Reserve & Surplus	2,530.79	(43.80)
Money received against share warrants	87.15	-
Total Equity	7,967.94	(26.60)
Liabilities		
(1) Non-Current Liabilities		
(a) Deferred Tax Liability	0.02	-
(b) Financial Liabilities		
(i) Borrowings	-	-
Total Non-Current Liabilities	0.02	-
(2) Current Liabilities		
(a) Financial Liabilities		
(i) Borrowings	-	57.17
(ii) Trade payables		
total outstanding dues of micro enterprises and small enterprises	0.31	0.67
total outstanding dues of creditors other than micro enterprises and small enterprises	1,203.43	0.74
(iii) Other Financial liabilities	2.56	2.41
(b) Other Current Liabilities	8.90	0.96
Total Current Liabilities	1,215.20	61.95
Total Equity and Liabilities	9,183.16	35.35
The accompanying notes are an integral part of the financial statements.		
As per our report of even date		
For M/s Bilimoria Mehta & Co. Chartered Accountants FRN: 101490W	 	For and on behalf of the Board Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)  Chairman & Managing Director DIN : 03137661 
CA Prakash Mehta Partner M.No: 090382 Date: 30th May 2024 Place of Signature: Mumbai UDIN: 24030382 BKFJBT5066.		

Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)

CIN: L86900MH1993PLC288371

Cash Flow Statement as at March 31, 2024

(Amount in lakhs)

PARTICULARS	For the year ended 31st March 2024	For the year ended 31st March 2023
A CASH FLOW FROM OPERATING ACTIVITIES		
Net Profit/(Loss) before tax and Extra Ordinary items	53.87	(0.13)
<u>Adjustment for:-</u>		
Finance Cost	1.58	1.65
Depreciation	0.08	
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	55.52	1.53
<u>Adjustment for:-</u>		
(Increase)/decrease Trade and other receivables	(1,253.04)	(17.06)
Increase/(decrease) Trade Payables	1,202.33	0.74
Increase/(decrease) Other Financial Current Liabilities	0.15	0.98
Increase/(decrease) Other Current Liabilities	7.94	
(Increase)/decrease Others Current Assets	-	(0.78)
(Increase)/decrease Others Non Current financial Assets	(0.08)	
CASH GENERATED FROM OPERATIONS	(42.70)	(16.11)
Direct Taxes Paid	(4.86)	-
I NET CASH FLOW FROM OPERATING ACTIVITIES	7.96	(14.59)
B CASH FLOW FROM INVESTING ACTIVITIES		
Purchase of Fixed Assets	(0.66)	-
Loans & Advances Given	(3,777.74)	-
II NET CASH USED IN INVESTING ACTIVITIES	(3,778.40)	-
C CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds from Issue of shares	3,826.00	-
Proceeds/(Repaid) from Long term Borrowings	(57.17)	16.77
TDS on Interest	-	(0.17)
Finance cost paid	(1.58)	-
III NET CASH USED IN FINANCING ACTIVITIES	3,767.25	16.60
NET INCREASE/(DECREASE) IN CASH OR CASH EQUIVALENTS (I + II + III)	(3.19)	2.02
<u>Add:- CASH & CASH EQUIVALENTS AS AT BEGNNING</u>	<u>3.58</u>	<u>1.56</u>
CLOSING BALANCE OF CASH & CASH EQUIVALENTS (Refer Note 2)	0.38	3.58

The accompanying notes are an integral part of the financial statements.
As per our report of even date

2-29'

Note 1. The above statement of cash flow has been prepared under the 'Indirect method' as set out in Indian Accounting

For M/s Bilimoria Mehta & Co.
Chartered Accountants
FRN: 101490W

CA Prakash Mehta
Partner

M.No: 030382

Date: 30th May 2024

Place of Signature: Mumbai

UDIN: 24030382 B K F J B T 5066.

For and on behalf of the Board
Fischer Medical Ventures Limited
(Formerly known as Fischer Chemic Limited)

Chairman & Managing Director

DIN: 03137661



Independent Auditor's Report on Standalone Annual Financial Results of the Company pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)

Opinion

We have audited the accompanying statement of Standalone Audited Annual Financial Results ('the Statement') of **Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)** for the year ended 31 March 2024, attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'), including relevant circulars issued by the SEBI from time to time.

1. In our opinion and to the best of our information and according to the explanations given to us, the Statement :

- (i) Is presented in accordance with the requirements of Regulation 33 of the Listing Regulations, and
- (ii) gives a true and fair view in conformity with the applicable Indian Accounting Standards ('Ind AS') prescribed under Section 133 of the Companies Act, 2013 ('the Act'), read with relevant rules issued thereunder, and other accounting principles generally accepted in India, of the standalone net profit after tax and other comprehensive income and other financial information of the Company year ended 31 March 2024.

Basis for Opinion

2. We conducted our audit in accordance with the Standards on Auditing ('SAs') specified under Section 143(10) of the Act. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Statement section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us, is sufficient and appropriate to provide a basis for our opinion

Responsibilities of Management and Those Charged with Governance for the Statement

3. This Statement has been prepared on the basis of the standalone annual audited financial statements and has been approved by the Company's Board of Directors. The Company's Board of Directors are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit or loss and other comprehensive income and other financial information of the Company in accordance with the accounting principles generally accepted in India, including Ind AS prescribed under Section 133 of the Act, read with relevant rules issued thereunder and other accounting principles generally accepted in India, and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that gives a true and fair view and is free from material misstatement, whether due to fraud or error.
4. In preparing the Statement, the Board of Directors is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern, and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations or has no realistic alternative but to do so.
5. The Board of Directors is also responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Statement

6. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing, specified under Section 143(10) of the Act, will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.
7. As part of an audit in accordance with the Standards on Auditing, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
 - Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of such controls. Under Section 143(3) (i) of the Act, we are also responsible for expressing our opinion on whether the Company has in place adequate internal financial controls with reference to financial statements and the operating effectiveness of such controls.

- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
 - Evaluate the appropriateness and reasonableness of disclosures made by the Board of Directors in terms of the requirements specified under Regulations 33 of the Listing Regulations.
 - Conclude on the appropriateness of the management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Statement or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Group to cease to continue as a going concern.
 - Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.
 - Materiality is the magnitude of misstatements in the Statement that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Statement may be influenced. We consider quantitative materiality and qualitative factors (i) in planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Statement.
8. We communicate with those charged with governance regarding among other matters, the planned scope and timing of the audit and significant audit findings including any significant deficiencies in internal control that we identify during our audit.
9. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Other Matter

10. The Statement includes the financial results for the quarter ended 31 March 2024, being the balancing figures between the audited figures in respect of the full financial year and the published unaudited year-to-date figures up to the third quarter of the current financial year, which were subject to limited review by us.

Our opinion is not modified in respect of above matters.

For Bilimoria Mehta & Co
Chartered Accountants
Firm Registration No.: 101490W



Prakash Mehta
Partner

Membership no. 030382
UDIN: 24030382BKFJBT5066
Place of Signature: Mumbai
Date: May 30, 2024

Amount (In Lakhs)

Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited)			
L24231MH1993PLC288371			
CONSOLIDATED BALANCE SHEET AS AT 31ST MARCH, 2024			
	Particulars	Note No.	As at 31st March, 2024
I.	ASSETS		-
	(1) Non - current assets		-
	(a) Property, Plant and Equipment	2	935.14
	(b) Intangible assets	3	-
	Goodwill		221.52
	(c) Capital work-in-progress	4	-
	(d) Right of use Asset		314.30
	(e) Financial assets		-
	(i) Investments	5	-
	(ii) Others	6	-
	(f) Deferred tax assets (net)	7	-
	(g) Other non - current assets	8	-
	(i) Investments		120.63
	(2) Current assets		-
	(a) Inventories	9	447.55
	(b) Financial assets		-
	(i) Investments		-
	(ii) Trade receivables	10	2,286.96
	(iii) Cash and cash equivalents	11	94.83
	(iv) Bank balances other than cash and cash equivalents	12	3,699.77
	(v) Other Current Financial Assets	13	305.31
	(c) Other current assets	14	206.14
	Total Assets		8,632.17
II.	EQUITY AND LIABILITIES		-
	(1) Equity		-
	(a) Equity Share capital	15	5,350.00
	(b) Other equity	16	-
	Reserve & Surplus		2,675.30
	Money received against share warrants		87.15
	Liabilities		-
	(2) Non - current liabilities		-
	(a) Financial liabilities	17	-
	(i) Long Term Borrowings		-
	Lease Liabilities		125.10
	(iii) Other Financial Liabilities		-
	(b) Deferred Tax Liability (net)		12.40
	(3) Current liabilities		-
	(a) Financial liabilities		-
	(i) Short Term Borrowings	18	-
	Lease Liabilities		42.60
	(ii) Trade payables	19	-
	a) Total outstanding dues of micro enterprises and small enterprises		79.88
	b) Total outstanding dues of creditors others than micro enterprises and small enterprises		135.67
	(iii) Other financial liabilities	20	102.80
	(b) Provisions	21	0.90
	(c) Other current liabilities	22	20.37
	Total Equity and Liabilities		8,632.17
	Significant accounting policies and estimates	1	-0.00
The accompanying notes 1 to 39 are an integral part of the financial As per our report of even date attached.			

For M/s Bilimoria Mehta & Co.
Chartered Accountants
FRN: 101490W

CA Prakash Mehta
Partner
M.No: 030382

Date: 30th May 2024

Place of Signature: Mumbai

UDIN: 24030382.BK.FJ.BV.6701

For and on behalf of the Board Fischer Medical Ventures Limited
(Formerly known as Fischer Chemic Limited)

Ravindran Govindan
Managing Director
DIN : 03137661



Amount (In Lakhs)

Fischer Medical Ventures Limited (Formerly known as Fischer Chemic Limited) CIN : L86900MH1993PLC288371 Consolidated PROFIT AND LOSS ACCOUNT FOR THE YEAR ENDED 31ST MARCH, 2024			
	Particulars	For the period 26th Jan	For the Year Ended
		to 31st March, 2024	31st March, 2024
I.	Revenue from operations	2,079.32	2,098.13
II.	Other income	46.78	50.12
III.	Total Income (I+II)	2,126.10	2,148.25
IV.	Expenses:		
	Cost of materials consumed	1,573.80	1,573.80
	Purchase of Traded Goods	7.87	7.87
	Changes in inventories of finished goods, by-products and work in progress	63.74	63.74
	Employee benefits expense	33.86	38.10
	Finance costs	5.18	6.76
	Depreciation and amortization expense	18.19	18.21
	Other expenses	148.18	228.66
	Total expenses (IV)	1,850.81	1,937.13
V.	Profit before tax (III-IV)	275.29	211.12
VI.	Tax expense :		
	Current tax	3.00	3.00
	Deferred tax	13.76	24.33
	Income tax relating to earlier years		-
		16.76	27.33
VII.	Profit for the year	258.53	183.79
VIII.	Other comprehensive income		
	(i) Items that will not be reclassified to profit or loss		
	Remeasurement of the net defined benefit liability/asset		-
	(ii) Income tax relating to items that will not be reclassified to profit or loss		-
	Total other comprehensive income, net of tax		
IX.	Total comprehensive income for the year		
X.	Earnings per equity share (Nominal value per share Rs. /-)		
	- Basic (Rs.)	0.65	1.65
	- Diluted (Rs.)	0.64	1.08

Note:

The acquisition of 'Time Medical International Ventures' has been done during the quarter four of the current financial year ended 31st March 2024. Since consolidation has been done in the current quarter, no comparatives of previous quarter ended 31st December 2023 and relevant corresponding comparative figures of previous periods i.e., quarter ended 31st March 2023 and year ended 31st March 2023 has not been presented in the financial result.

For M/s Bilimoria Mehta & Co.
Chartered Accountants
FRN: 101490W

CA Prakash Mehta
Partner
M.No: 030382
Date: 30th May 2024
Place of Signature: Mumbai

UDIN: 24030382BKFBV6701

For and on behalf of the Board
Fischer Medical Ventures Limited
(Formerly known as Fischer Chemic Limited)

Ravindran Govindan
Managing Director
DIN : 03137661



Fischer Medical Ventures Limited (Formerly known as Fischer Chemich Limited) CIN - 186900MH1993PLC288371 Cash Flow Statement as at March 31, 2024 (Amount in lakhs)	
PARTICULARS	For the year ended 31st March 2024
A CASH FLOW FROM OPERATING ACTIVITIES	
Net Profit/(Loss) before tax and Extra Ordinary items	211.12
Adjustment for:-	
Finance Cost	2.68
Depreciation	9.05
Depreciation on ROU	9.16
Interest On lease Liability	4.08
OPERATING PROFIT BEFORE WORKING CAPITAL CHANGES	236.09
Adjustment for:-	
(Increase)/decrease Inventories	1,752.11
(Increase)/decrease Trade and other receivables	(3,470.94)
Increase/(decrease) Trade Payables	993.89
Increase/(decrease) Other Financial Current Liabilities	100.39
Increase/(decrease) Other Current Liabilities	(8.69)
(Increase)/decrease Others Financial Assets	(294.90)
(Increase)/decrease Others Current Assets	(38.29)
CASH GENERATED FROM OPERATIONS	(966.43)
Direct Taxes Paid	(4.86)
I NET CASH FLOW FROM OPERATING ACTIVITIES	(735.20)
B CASH FLOW FROM INVESTING ACTIVITIES	
Purchase of Fixed Assets	(48.49)
ROU	(0.00)
Sale of Investments	(3,090.00)
Loans & Advances Given	(0.08)
II NET CASH USED IN INVESTING ACTIVITIES	(3,138.58)
C CASH FLOW FROM FINANCING ACTIVITIES	
Proceeds from Issue of shares	3,826.00
Lease Liability	(60.44)
Proceeds/(Repaid) from Long term Borrowings	(57.17)
Finance cost	(2.68)
III NET CASH USED IN FINANCING ACTIVITIES	3,705.72
NET INCREASE/(DECREASE) IN CASH OR CASH EQUIVALENTS (I + II + III)	(168.07)
Add:- CASH & CASH EQUIVALENTS AS AT BEGINNING	3.58
Add:- CASH & CASH EQUIVALENTS POST ACQUISITION	259.32
CLOSING BALANCE OF CASH & CASH EQUIVALENTS (Refer Note 2)	94.83
	94.83
The accompanying notes are an integral part of the financial statements.	-0.00
As per our report of even date	

The accompanying notes are an integral part of the financial statements. -0.00
As per our report of even date

Note 1. The above statement of cash flow has been prepared under the 'Indirect method' as set out in Indian Accounting Standard (Ind AS) 7- Statement of Cash flows.

For M/s Bilimoria Mehta & Co.
Chartered Accountants
FRN: 101490W

For and on behalf of the Board Fischer Medical Ventures Limited
(Formerly known as Fischer Chemich Limited)

[Signature]
CA Prakash Mehta
Partner
M.No: 030382
Date: 30th May 2024
Place of Signature: Mumbai
UDIN: 24030382BKFBV6701

[Signature]
Ravindran Govindan
Managing Director
DIN : 03137661

[Stamp]
Fischer Medical Ventures Limited



Independent Auditor's Report on Consolidated Annual Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended)

To the Board of Directors of

Fischer Medical Ventures Limited

(Formerly known as Fischer Chemic Limited)

Shop No. 104, 1st Floor Raghuleela Mall,

Behind Poisor Bus Depot, Kandivali (W),

Mumbai: 400067

Opinion

We have audited the accompanying consolidated annual financial results ('the Statement') of **Fischer Chemic Limited** ('the Holding Company') and its subsidiaries (the Holding Company and its subsidiaries together referred to as 'the Group'), for the quarter ended 31st March 2024 and for the year ended March 31st March 2024, attached herewith, being submitted by the Holding Company pursuant to the requirements of [Regulation 33] of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (as amended) ('Listing Regulations'),

1. In our opinion and to the best of our information and according to the explanations given to us and based on the consideration of the reports of other auditors on separate audited financial results and on the other financial information of the subsidiaries as referred to in paragraph 11 below, the Statement:
 - (i) Includes the annual financial results of its subsidiary (Times Medical International Ventures (India) Pvt Ltd).
 - (ii) And presents financial results in accordance with the requirements of Regulation 33 of the Listing Regulations, and
 - (iii) Gives a true and fair view in conformity with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') prescribed under section 133 of the Companies Act, 2013 ('the Act') read with the Companies (Indian Accounting Standards) Rules, 2015, and other accounting principles generally accepted in India, of the consolidated net profit/loss after tax and other comprehensive income and other financial information of the Group, for the), for the quarter ended 31st March 2024 and for the year ended March 31st March 2024

Date: 30th May 2024

To,

The Department of Corporate Services,
Bombay Stock Exchange Limited,
14th Floor, P.J. Towers, Dalal Street,
Mumbai 400001.
BSE Scrip Code: 524743

Dear Sir / Madam,

Reg: Details of Outstanding Qualified Borrowings and Incremental Qualified Borrowings for FY 2024

With reference to SEBI circular no. SEBI/HO/DDHS/DDHS-RACPODI/P/CIR/2023/172 dated October 19, 2023, and pursuant to email communication received from NSE and BSE, details of Outstanding Qualified Borrowings and Incremental Qualified Borrowings for the financial year ended March 31, 2024 are provided below:

S.No.	Particulars	Details
i.	Outstanding Qualified Borrowings at the start of the financial year (Rs. In Crores)	-
ii.	Outstanding Qualified Borrowings at the end of the financial year (Rs. In Crores)	-
iii.	Highest credit rating of the company relating to the unsupported bank borrowings or plain vanilla bonds, which have no structuring/support built in	-
iv.	Incremental borrowing done during the year (qualified borrowing) (Rs. In Crores)	-
v.	Borrowings by way of issuance of debt securities during the year (Rs. In Crores)	-

For **FISCHER MEDICAL VENTURES LIMITED**

(Formerly known as Fischer Chemic Limited)



RAVINDRAN GOVINDAN

CHAIRMAN & MANAGING DIRECTOR



Basis for Opinion

2. We conducted our audit in accordance with the Standards on Auditing specified under section 143(10) of the Act. Our responsibilities under those standards are further described in *the Auditor's Responsibilities for the Audit of the Statement* section of our report. We are independent of the Group, its associates and joint ventures, in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India ('the ICAI') together with the ethical requirements that are relevant to our audit of the financial results under the provisions of the Act, and the rules thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us together with the audit evidence obtained by the other auditors in terms of their reports referred to in paragraph 11 of the Other Matter section below is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management and Those Charged with Governance for the Statement

3. The Statement, which is the responsibility of the Holding Company's management and has been approved by the Holding Company's Board of Directors, has been prepared on the basis of the consolidated annual financial statements. The Holding Company's Board of Directors is responsible for the preparation and presentation of the Statement that gives a true and fair view of the consolidated net profit or loss and other comprehensive income, and other financial information of the Group including its associates and joint ventures in accordance with the Ind AS prescribed under section 133 of the Act read with the Companies (Indian Accounting Standards) Rules, 2015 and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The Holding Company's Board of Directors is also responsible for ensuring accuracy of records including financial information considered necessary for the preparation of the Statement. Further, in terms of the provisions of the Act, the respective Board of Directors of the companies included in the Group, are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act, for safeguarding of the assets of the Group, and its associates and joint ventures, and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively, for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial results, that give a true and fair view and are free from material misstatement, whether due to fraud or error. These financial results have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.
4. In preparing the Statement, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group, to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting, unless the respective Board of Directors/ management either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.
5. Those respective Board of Directors are also responsible for overseeing the financial reporting process of the companies included in the Group.

Auditor's Responsibilities for the Audit of the Statement

6. Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Act will always detect a material misstatement, when it exists. Misstatements can arise from fraud or error, and are considered material if, individually, or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this Statement.
7. As part of an audit in accordance with the Standards on Auditing specified under section 143(10) of the Act, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:
 - Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;
8. We communicate with those charged with governance of the Holding Company, regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.
9. We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.
10. We also performed procedures in accordance with SEBI Circular CIR/CFD/CMD1/44/2019 dated 29 March 2019, issued by the SEBI under Regulation 33 (8) of the Listing Regulations, to the extent applicable.

Other Matters

11. We did not audit the annual financial statements/ financial information/ financial results of its subsidiary included in the Statement, whose financial information reflects total assets of ₹ 82,13,89,689.85 as at 31st March 2024, total revenues of ₹ 22,28,13,277.76 total net loss after tax of ₹ 1,19,84,896.36 , total comprehensive income/(loss) of ₹ Nil , and cash flows (net) of ₹ 35,29,72,122.18 , for the year ended on that date, as considered in the as considered in the respective audited separate annual financial result of the entities included in the group. These Annual Financial results have been audited by others auditors whose audit report(s) have been furnished to us by the management, and our opinion in so far as its relates to the amounts and disclosures included in the respect of these subsidiary is based solely on the audit report(s) of such other auditors, and the procedures performed by us as stated in paragraph 9 above.

Our opinion is not modified in respect of above matter (s) with respect to our reliance on the work done by and the reports of the other auditors.

For Bilimoria Mehta & Co
Chartered Accountants
Firm Registration No.: 101490W



Prakash Mehta

Partner

Membership no. 030382

UDIN: 24030382BKFJBV6701

Place of Signature: Mumbai

Date: May 30, 2024

May 30, 2024

Declaration under Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

I, RAVINDRAN GOVINDAN, Chairman & Managing Director of FISCHER MEDICAL VENTURES LIMITED (Formerly known as Fischer Chemic Limited) (CIN: L24231MH1993PLC288371) having its Registered Office at 104, First Floor Raghuleela Mega Mall, Behind Poisar Depot, Kandivali West Mumbai, Maharashtra, 400067, hereby declare that the Statutory Auditor M/s. Bilimoria Mehta & Co., Chartered Accountants, Mumbai, Chennai (FRN: 101490W) have issued an Audit Report (Standalone and Consolidated) with unmodified opinion on Audited Financial Results of the Company for the Quarter and Financial Year ended 31/03/2024. This declaration is given in compliance to Regulation 33(3) (d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Please take the same on your record and oblige.

Thanking You,
Yours Truly,

For **FISCHER MEDICAL VENTURES LIMITED**
(Formerly known as Fischer Chemic Limited)



RAVINDRAN GOVINDAN
CHAIRMAN & MANAGING DIRECTOR



ANNEXURE - 3

Details under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Name	Jacob Thomas
DIN	10639814
Reason for Change	Board has recommended the appointment as an Independent Director of the Company for a term of Five years for the approval of Shareholders by a Special Resolution through ensuing Postal Ballot Process.
Brief profile (in case of appointment)	Enclosed Below
Disclosure of relationships between Directors	Not related with any Director

PROFILE OF DR. JACOB THOMAS

Dr. Jacob Thomas, recommended for Appointment as an Independent Director in the ensuing Postal Ballot process to the Shareholders of the Company, epitomizes the essence of innovation and leadership in the healthcare realm. He started as an emergency medicine doctor educated in India, United Kingdom, and the United States and eventually moved up the corporate ladder having served in various capacities at Subang Jaya Medical Centre, and became the CEO and Group Medical Advisor of Sime Darby Health Care, and now Chairman of Ramsay Sime Darby Health Care, a position he held since 2013. Dr. Jacob was the longest-standing President of the Association of Private Hospitals of Malaysia having been elected five times since 2008 and became President of Asian Hospital Federation from 2012-2013. He also serve as Councilor of the Malaysian Society for Quality in Health (MSQH) and Board Member of the Malaysia Healthcare Travel Council (MHTC), and works closely with various NGOs and Government agencies to promote Malaysian Healthcare both locally and internationally. Malaysia Prime Minister thereafter appointed him to head the Healthcare Sector of the National Productivity Council in 2018. In 2022, Dr Jacob was appointed Chairman of the globally-renowned accreditation agency in the US Joint Commission International (JCI) and Joint Commission Resources (JCR) and also a Steering Committee Member of Malaysia's National Key Economic Areas (NKEA) for Healthcare and Chairman of the Disciplinary Committee of Malaysian Medical Council. Dr. Jacob was conferred the title of Dato' by Sultan Sharafuddin Idris Shah for his various achievements in Malaysia.

Details under Regulation 30 of the Listing Regulations read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023.

Name	Mr. Roberto M Pagdanganan
DIN	10639820
Reason for Change	Board has recommended the appointment as an Independent Director of the Company for a term of Five years for the approval of Shareholders by a Special Resolution through ensuing Postal Ballot Process.
Brief profile (in case of appointment)	Enclosed Below
Disclosure of relationships between Directors	Not related with any Director

PROFILE OF MR. ROBERTO M PAGDANGANAN

Gov. Roberto M. Pagdanganan, recommended for Appointment as an Independent Director in the ensuing Postal Ballot process to the Shareholders of the Company, holds academic accolades including a Summa Cum Laude degree in B.S. Chemical Engineering from MLQU and a Doctorate in Education Management from Bulacan University. With a legacy of leadership spanning various sectors, Gov. Roberto is a stalwart figure in Philippine governance and public service. Gov. Roberto served as Governor of the Province of Bulacan from 1986 to 1998, leaving an indelible mark on its development. His tenure as President of the League of Provinces of the Philippines and Founding Chairman of the League of Leagues of LGUs (now Union of Local Authorities of the Philippines) underscore his commitment to advancing provincial interests. Having held key ministerial positions including Secretary of the Department of Tourism and Secretary of the Department of Agrarian Reform, Gov. Roberto demonstrated his versatility and dedication to national development. His leadership as Chairman of the Cooperative Development Authority and the Philippine Southeast Asian Games Organizing Committee further exemplifies his multifaceted contributions to Philippine governance. A recipient of the Presidential Legion of Honor, Gov. Roberto has been recognized for his exceptional service to the nation. His commitment to youth development is evident through his past roles as National President of the Boy Scouts of the Philippines and District Governor of the Rotary Club. During his tenure as Chairman of the Medicine Transparency Alliance Philippines and the Health and Retirement Tourism Alliance of the Philippines, he championed various initiatives aimed at enhancing healthcare and tourism sectors. Currently, Gov. Roberto serves as Advisor to HealthCore and Chairman of Digihealth Specialists to continue to make profound strides in shaping the future of healthcare and technology in the Philippines.